EQT Life Sciences backs Kinaset Therapeutics' USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
PR Newswire —
EQT Life Sciences invests in U.S.-based Kinaset Therapeutics – a clinical-stage biopharma company developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases Proceeds from the oversubscribed USD 103 million Series B round to help advance frevecitinib –...